Pancreatic neuroendocrine tumours (PNENs) are an under-studied type of tumour that are rare but clinically challenging due to late detection, variable progression and frequent metastasis. The molecular basis of PNENs is not well understood and there are no prognostic markers to aid PNEN clinical management. The overall aim of this study is to provide a comprehensive molecular characterization of PNENs to better understand disease progression and heterogeneity, and to devise clinically relevant subclasses. By integrating RNA-sequencing based transcriptome profiling and an innovative new technology for proteomic profiling of tumour specimens, their study will explore the proteogenomic landscape of PNENs. In addition to identifying disease classifiers, this study will lay the groundwork for further investigations of candidate biomarkers, potential driver mutations and therapeutic targets.
Molecular dissection of Pancreatic Neuroendocrine Tumors
Canada’s Michael Smith Genome Sciences Centre respectfully acknowledges that we operate on the traditional, ancestral and unceded territories of the xʷməθkwəy̓əm (Musqueam), Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), and Skwxwú7mesh (Squamish) nations who have cared and nurtured this land for all time. We give thanks, as uninvited guests, to be able to live and work on these lands.
